Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Wasserman

Showing results (201-210 of 229) with videos related to

Pageof 23
Sort By:
Cell|December 9, 2014
Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instabilityFei-Long Meng, Zhou Du, Alexander Federation, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 17, 2012
Crystal structure of the human PRMT5:MEP50 complexStephen Antonysamy, Zahid Bonday, Robert M Campbell, et al.
Journal of Medicinal Chemistry|October 5, 2001
Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha releaseC B Xue, X He, R L Corbett, et al.
Frontiers in Genetics|March 13, 2023
A combination of HLA-DP α and β chain polymorphisms paired with a SNP in the DPB1 3' UTR region, denoting expression levels, are associated with atopic dermatitisDavid J Margolis, Jamie L Duke, Nandita Mitra, et al.
Journal of Medicinal Chemistry|October 5, 2001
Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitorsW Yao, Z R Wasserman, M Chao, et al.
JAMA Network Open|August 19, 2024
Modeling Nursing Home Harms From COVID-19 Staff Furlough PoliciesSarah M Bartsch, Colleen Weatherwax, Bruce Leff, et al.
Protein Engineering, Design & Selection : PEDS|February 13, 2010
Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutantShane Atwell, Christie G Brouillette, Kris Conners, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2003
Potent and selective aggrecanase inhibitors containing cyclic P1 substituentsRobert J Cherney, Ruowei Mo, Dayton T Meyer, et al.
Transactions of the Association of American Physicians|January 1, 1981
Influence of therapy on causes of death in polycythemia veraL R Wasserman, S P Balcerzak, P D Berk, et al.
Journal of the American Medical Directors Association|March 3, 2024
How the Timing of Annual COVID-19 Vaccination of Nursing Home Residents and Staff Affects Its ValueSarah M Bartsch, Colleen Weatherwax, Michael R Wasserman, et al.
Pageof 23

Showing results (201-210 of 229) with videos related to

Sort By:
Pageof 23
Cell|December 9, 2014
Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instabilityFei-Long Meng, Zhou Du, Alexander Federation, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 17, 2012
Crystal structure of the human PRMT5:MEP50 complexStephen Antonysamy, Zahid Bonday, Robert M Campbell, et al.
Journal of Medicinal Chemistry|October 5, 2001
Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha releaseC B Xue, X He, R L Corbett, et al.
Frontiers in Genetics|March 13, 2023
A combination of HLA-DP α and β chain polymorphisms paired with a SNP in the DPB1 3' UTR region, denoting expression levels, are associated with atopic dermatitisDavid J Margolis, Jamie L Duke, Nandita Mitra, et al.
Journal of Medicinal Chemistry|October 5, 2001
Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitorsW Yao, Z R Wasserman, M Chao, et al.
JAMA Network Open|August 19, 2024
Modeling Nursing Home Harms From COVID-19 Staff Furlough PoliciesSarah M Bartsch, Colleen Weatherwax, Bruce Leff, et al.
Protein Engineering, Design & Selection : PEDS|February 13, 2010
Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutantShane Atwell, Christie G Brouillette, Kris Conners, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2003
Potent and selective aggrecanase inhibitors containing cyclic P1 substituentsRobert J Cherney, Ruowei Mo, Dayton T Meyer, et al.
Transactions of the Association of American Physicians|January 1, 1981
Influence of therapy on causes of death in polycythemia veraL R Wasserman, S P Balcerzak, P D Berk, et al.
Journal of the American Medical Directors Association|March 3, 2024
How the Timing of Annual COVID-19 Vaccination of Nursing Home Residents and Staff Affects Its ValueSarah M Bartsch, Colleen Weatherwax, Michael R Wasserman, et al.
Pageof 23